Updated:
GeneScience Pharmaceuticals Co.
Founded in 1997, GeneScience Pharmaceuticals is a subsidiary of state-controlled Changchun High-Tech (SZ000661).
GeneScience Pharmaceuticals Co.
Founded in 1997, GeneScience Pharmaceuticals is a subsidiary of state-controlled Changchun High-Tech (SZ000661). The firm’s chief scientist holds a PhD from the University of California and has won China’s State Science and Technology Progress Award. Administrative headquarters are in Changchun, with operational headquarters in Shanghai. The firm focuses on endocrinology, oncology, immunology, and women's health. It operates more than 80 innovative drug programs, 40-plus in clinical stages, including over 35 Class 1 new drugs. Key products include recombinant human growth hormone (sold as Saizeng and JinSaiZeng) and the first long-acting growth hormone injection. In 2025, a pipeline deal with Yarrow Bioscience was valued at $1.365 billion upfront and milestones. GeneScience employs over 8,000 people across 10 global R&D and production centers in China, the US, Switzerland, and the UK. The firm’s products reach more than 40 countries. In 2025, near 20 core projects entered pivotal clinical stages. The firm also operates a charitable arm, with honors from the China Red Cross Society. As a subsidiary of a state-owned enterprise, GeneScience operates with a hybrid governance model — commercial pharmaceutical R&D under state ownership. Its chief scientist also serves as general manager, a concentration of board and executive roles that differs from most Western biotech governance.
General information
Firm type
other
Year founded
1997
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Changchun
Corporate office
Changchun, China
Additional offices
Shanghai · Mountain View · Basingstoke · Shenzhen · San Francisco · Basel · London · Taipei
Principals
unspecified
总经理, 首席科学家
Sector focus
Frequently asked questions
Who runs investment decisions at GeneScience Pharmaceuticals?
The firm’s chief scientist — who also serves as general manager and holds a PhD from the University of California — leads both R&D and corporate strategy. The board is ultimately controlled by state-owned Changchun High-Tech (SZ000661).
How does GeneScience source proprietary drug development?
GeneScience uses AI-driven molecular design and four core technology platforms: AI, precision targeting, multifunctional molecules, and long-acting formulations. It also in-licenses foreign assets and out-licenses its own molecules globally, as demonstrated by the 2025 Yarrow deal.
Is GeneScience structured as a family office?
No. GeneScience is a state-controlled pharmaceutical subsidiary with shares publicly traded via parent Changchun High-Tech. It does not operate as a wealth management or investment vehicle for any family.
What investment stages does GeneScience typically target?
GeneScience focuses on preclinical through Phase III clinical development. It has 40-plus assets in clinical phases and over 35 Class 1 new drugs. It also commercializes approved drugs across 40-plus countries.
Which sectors does GeneScience explicitly avoid?
The firm does not publicly disclose excluded sectors. Its stated focus is endocrinology, oncology, women’s health, immunology, and rare diseases.
How is GeneScience related to Changchun High-Tech?
GeneScience is a controlled subsidiary of Changchun High-Tech (stock code SZ000661), a state-owned enterprise listed on the Shenzhen Stock Exchange. Changchun High-Tech consolidates GeneScience’s financial results.
Does GeneScience maintain philanthropic structures?
Yes. GeneScience has received the China Red Cross Society’s Special Contribution Award and was named a "Charity Model" by the China Charity List. However, the firm does not separately disclose a dedicated foundation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: